Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Two-Drug combo beat whipworm in kids?

NCT ID NCT07661316

Disease control Sponsor: Mundo Sano Foundation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether combining two drugs—albendazole and ivermectin—works better than the standard single drug for treating whipworm infection in schoolchildren aged 6 to 15 in Honduras. Participants receive a single dose of either placebo, albendazole alone, albendazole plus ivermectin, or a fixed-dose combination tablet. The study measures cure rates and side effects, aiming to find a more effective treatment for this common intestinal worm infection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
albendazole and ivermectin
What this could lead to
If successful, this combination could offer a more effective, single-dose treatment for whipworm and other soil-transmitted worms, simplifying control programs in affected regions.
What could go wrong
This is a single trial in one region, and results may not apply elsewhere. The combination may cause more side effects than standard treatment, and cure rates may still be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 368 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 15 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Trichuris trichiura infection documented by quantitative real-time PCR (qPCR) performed within 30 days prior to randomization. * Age 6 to 15 years inclusive. * Written informed consent provided by a parent or legal guardian. Assent provided by children aged 9 years or older, according to local ethical requirements. Exclusion Criteria: * Known allergy or hypersensitivity to albendazole or ivermectin. * Receipt of an anthelmintic treatment (albendazole, mebendazole, or ivermectin) within 3 months prior to enrollment. * Participation in another clinical trial within 3 months prior to enrollment. * Severe comorbidity at the investigator's discretion (e.g., diarrhea, tuberculosis, or malaria). * Body weight \<15 kg. * Positive pregnancy test or refusal to undergo pregnancy testing in post-menarcheal girls and female adolescents of childbearing potential.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ascariasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ancylostomiasis ascariasis helminthiasis Hookworm Infections hookworm infectious disease strongyloidiasis trichuriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ascariasis Hookworm infection Soil-transmitted helminthiasis Strongyloidiasis Trichuriasis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Instituto de Investigaciones en Microbiología, Facultad De Ciencias, Universidad Nacional Autónoma de Honduras

    Tegucigalpa, 11101, Honduras

More trials for these conditions

Other studies related to the condition(s) this trial covers.